<DOC>
	<DOCNO>NCT02734667</DOCNO>
	<brief_summary>The purpose study learn impact continuous glucose monitoring ( CGM ) family newly diagnose child type 1 diabetes ( T1D ) . The investigator hope learn continuous glucose monitoring affect glycemic variable diabetes-related distress .</brief_summary>
	<brief_title>Initiation Continuous Glucose Monitoring Diagnosis Type 1 Diabetes</brief_title>
	<detailed_description>Synopsis study protocol This pilot randomize clinical trial compare newly diagnose T1D youth start CGM ( intervention group ) versus ( control group ) . The investigator examine group difference 6-month period ( Phase 1 ) two set outcome : psychosocial variable glycemic variable . After initial comparison intervention control across first six month diagnosis , investigator conduct longitudinal follow-up ( Phase 2 ) glycemic psychosocial variable additional 18 month . The CGM system use study Dexcom G5 System Share function ( FDA Approved ) . An IDE obtain use system non-adjunctive manner . Participants complete Phase 1 six month . Phase 2 include 3 assessment conduct every six month participant two year post-diagnosis . Study Procedures Participants recruit two center : Stanford University Barbara Davis Center Diabetes , University Colorado . Participants enrol inpatient within 1 month diagnosis . Once identify , study staff approach potential participant explain study , determine eligibility , obtain informed consent . Once enrolled study , participant randomize . Participants randomize 2:1 ratio , intervention control . The investigator also stratify age group ensure equal representation age across group . The age group ( year ) 2-6 , 7-11 , 12-17 . To ensure safety young group , recruitment participant age 2-6 year group begin investigator least 2 week non-adjunctive CGM use data least 3 participant age 7-17 year . Data review DSMB 3 participant deem safe DSMB , investigator start enrol participant young age group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible study , child must meet following criterion : 1 . Diagnosis type 1 diabetes accord American Diabetes Association diagnostic criterion 2 . Time since diagnosis longer one month 3 . Age 2 17 year 4 . Parental consent ( assent child applicable ) participate study 5 . No severe medical condition , opinion investigator likely hinder participation clinical trial . To eligible study , parent must meet following criterion : 1 . Parent legal guardian child type 1 diabetes meet `` child '' criterion outline 2 . Age 18.0 year old 3 . Parent comprehend write English 4 . Parent understand study protocol sign inform consent document The presence follow exclusion study : 1 . Child medical disorder judgment investigator interfere completion aspect protocol ( e.g. , pregnancy , kidney disease , adrenal insufficiency , skin condition may hinder sensor application ) . 2 . Child neurologic disorder judgment investigator affect completion protocol 3 . Current use oral glucocorticoid medication , judgment investigator would contraindication participation study 4 . Child unable completely avoid acetaminophen duration study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>